Exploring the significance of collecting patient reports based on international pharmacovigilance experience

doi:10.19803/j.1672-8629.20230247

Abstract

Abstract: Objective To explore the significance of enterprises collecting patient reports as stated in Good Pharmacovigilance Practice (GVP). Methods Review the literature about the research findings from various nations and discuss the value of patient reports to reveal the importance of collecting patient reports. Results and Conclusion Patient reports are a beneficial supplement to doctor reports and are conducive to signal detection. Enterprises should take patient reports seriously, establish paths for collecting patient reports, and ensure the paths work efficiently.

Key words: patient reports, pharmacovigilance, adverse drug reaction, good pharmacovigilance practice, marketing authorization holder

CLC Number:

R917

PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.

References

[1] World Health Organization.Safety monitoring of medical products: reporting system for the general public[R/OL]. [2023-04-07].https://apps.who.int/iris/bitstream/handle/10665/336225/9789241503198-eng.pdf.
[2] NMPA.NMPA announcement on issuing good pharmacovigilance practices (No.65 of2021) [EB/OL].(2021-05-13)[2023-04-07]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html.
[3] World Health Organization. International drug monitoring: the role of national centers. Geneva: World Health Organization[R/OL]. (1972-09-20) [2023-07-17]. https://apps.who.int/iris/bitstream/handle/10665/40968/WHO_TRS_498.pdf;jsessionid=E3A16FD9966B979CFCDA0464186AD7DF?sequence=1.
[4] PIRMOHAMED M, JAMES S, MEAKIN S, et al.Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients[J]. BMJ, 2004, 329: 15-19.
[5] KONGKAEW C, NOYCE PR, ASHCROFT DM.Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies[J]. Annals of Pharmacotherapy, 2008, 42(7/8): 1017-1025.
[6] BEIJER HDE, BLAEY C.Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies[J]. Pharmacy World & Science Pws, 2002, 24(2): 46-54.
[7] MEHTA UC.Pharmacovigilance: the devastating consequences of not thinking about adverse drug reactions: The burden of adverse drug reactions (ADRs) on patient care has been found to be high globally and is particularly high in South Africa[J]. Continuing Medical Education, 2011, 29(6): 247-251.
[8] SIENKIEWICZ K, BURZYŃSKA M, RYDLEWSKA-LISZKOWSKA I, et al. The Importance of direct patient reporting of adverse drug reactions in the safety monitoring process[J]. Int J Environ Res Public Health, 2021,413:1-16.
[9] INÁCIO P, CAVACO A, AIRAKSINEN M. The value of patient reporting to the pharmacovigilance system: a systematic review[J]. Br J Clin Pharmacol, 2017, 83: 227-246.
[10] PILLAY S, MULUBWA M, VILJOEN M.Parental reporting of adverse drug reactions in South africa: an online survey[J]. Afr J Prim Health Care Fam Med, 2021, 13(1): 1-8.
[11] SABBLAH GT, DARKO DM, MOGTARI H, et al.Patients' perspectives on adverse drug reaction reporting in a developing country: a case study from ghana[J]. Drug Saf, 2017, 40: 911-921.
[12] JARERNSIRIPORNKUL N, PATSUREE A, KRSKA J.Public confidence in ADR identification and their views on ADR reporting: mixed methods study[J]. Eur J Clin Pharmacol, 2017, 73(2): 223-231.
[13] HARIRAJ V, AZIZ Z.Patient reporting of adverse drug reactions (ADRs): survey of public awareness and predictors of confidence to report[J]. Ther Innov Regul Sci, 2018, 52(6): 757-763.
[14] AL DWEIK R, STACEY D, KOHEN D, et al.Factors affecting patient reporting of adverse drug reactions: a systematic review[J]. Br J Clin Pharmacol, 2017, 83: 875-883.
[15] JACOBS TG, HILDA AMPADU H, HOEKMAN J, et al.The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study[J]. BMC Public Health, 2018, 18(1): 1384-1394.
[16] MATOS C, VAN HUNSEL F, JOAQUIM J.Are consumers ready to take part in the pharmacovigilance system?—a portuguese preliminary study concerning ADR reporting[J]. European Journal of Clinical Pharmacology, 2015, 71(7): 883-890.
[17] European Medicines Agency. Guidelines on Good Pharmacovigilance Practices[EB/OL].(2012-06-25)[2023-05-21].https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.
[18] Code of Federal Regulations. 21 CFR, section 314.80. Postmarketing reporting of adverse drug experiences[EB/OL]. (2014-06-10) [2023-05-21].https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314#314.80.
[19] U.S. Food & Drug Administration. Post Marketing Safety Reporting for Human Drug and Biological Products Including Vaccines (Draft Guidance for Industry) [EB/OL]. (2020-01-29)[2023-05-21]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines.
[20] MOH. Regulations for the administration of adverse drug reaction reporting and monitoring (No.81, 2011) [EB/OL]. (2011-05-04)[2023-04-13].https://gkml.samr.gov.cn/nsjg/bgt/202106/t20210629_331741.html.
[21] NMPA.NMPA announcement on direct reporting of adverse reactions by drug marketing authorization holders (No. 66, 2018) [EB/OL].(2018-09-30)[2023-04-13]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20180930174301286.html.
[22] Standing Committee of the National People's Congress. Drug Administration Law of the People's Republic of China[EB/OL].(2019-08-26)[2023-04-13]. https://www.gov.cn/xinwen/2019-08/26/content_5424780.htm.
[23] KRSKA J, ANDERSON C, MURPHY E, et al.How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme[J]. Drug Saf, 2011, 34(5): 429-436.
[24] BASCH E, ARTZ D, DULKO D, et al.Patient online self-reporting of toxicity symptoms during chemotherapy[J]. J Clin Oncol, 2005, 23(15): 3552-3561.
[25] KINNUNEN UM, SARANTOB K.It is time for self-incident-reporting for patients and their families in every health care organization: a literature review[J]. Stud Health Technol Inform, 2013, 192: 92-96.
[26] ROLFES L, WILKES S, VAN HUNSEL F, et al.Important information regarding reporting of adverse drug reactions: a qualitative study[J]. Int J Pharm Pract, 2014, 22: 231-233.
[27] ROLFES L, VAN HUNSEL F, VAN DER LINDEN L, et al. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis[J]. Drug safety, 2017, 40(7): 607-614.
[28] VAN GROOTHEEST A, PASSIER J, VAN PUIJENBROEK E.Direct reporting of side effects by the patient: favourable experience in the first year[J].Nederlands Tijdschrift Voor Geneeskunde, 2005, 149(10): 529-533.
[29] DEFER G, FEDRIZZI S, CHEVANNE D, et al.Adverse drug reaction reporting using a mobile device application by persons with multiple sclerosis: a cluster randomized controlled trial[J]. Drug Saf, 2021, 44: 223-233.
[30] ROLFES L, VAN HUNSEL F, WILKES S, et al.Adverse drug reaction reports of patients and healthcare professionals-differences in reported information[J]. Pharmacoepidemiol Drug Saf, 2015, 24(2): 152-158.
[31] BANOVAC M, CANDORE G, SLATTERY J, et al.Patient reporting in the EU: analysis of eudraVigilance Data[J]. Drug Saf, 2017, 40: 629-645.
[32] BLENKINSOPP A, WILKIE P, WANG M, et al.Patient reporting of suspected adverse drug reactions: a review of published literature and international experience[J]. Br J Clin Pharmacol, 2007, 63(2): 148-156.
[33] AVERY AJ, ANDERSON C, BOND CM, et al.Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys[J]. Health Technol Assess, 2011, 15(1): 1-8.
[34] O'DONOVAN B, RODGERS RM, COX AR, et al. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme[J]. Br J Clin Pharmacol, 2022, 88(7): 3434-3446.
[35] DE LANGEN J, VAN HUNSEL F, PASSIER A, et al.Adverse drug reaction reporting by patients in the Netherlands: three years of experience[J]. Drug Saf, 2008, 31(6): 515-524.
[36] NASRALLAH-IRLES D, CASTOT A, THOMAS L, et al.Adverse drug reactions: a pilot study on patient reporting through patient associations[J]. Therapie, 2008, 63(5): 385-392.
[37] FOSTER JM, VAN DER MOLEN T, JONG-VAN DEN BERG L. Patient-reporting of side effects may provide an important source of information in clinical practice[J]. Eur J Clin Pharmacol, 2007, 63(10): 979-981.
[38] European Medicines Agency. Guidelines on Good Pharmacovigilance Practices[EB/OL].(2012-06-25)[2023-07-17].https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf.
[39] HÄRMARK L, VAN HUNSEL F, GRUNDMARK B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish Systems[J]. Drug Saf, 2015, 38(4): 337-347.
[40] HAZELL L, CORNELIUS V, SHAKIR S, et al.Patient reporting of ADRs in the UK: How do patient reports affect potential signals generated by healthcare professionals?[J]. Drug Safety, 2009, 1311: 971.
[41] EGBERTS TC, SMULDERS M, DE KONING FH, et al.Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals[J]. BMJ, 1996, 313(7056): 530-531.
[42] VAN HUNSEL F, PASSIER A, VAN GROOTHEEST K.Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example[J]. Br J Clin Pharmacol, 2009, 67(5): 558-564.
[43] HAMMOND IW, RICH DS, GIBBS TG.Effect of consumer reporting on signal detection: using disproportionality analysis[J]. Expert Opinion on Drug Safety, 2007, 6(6): 705-712.
[44] PARRETTA E, RAFANIELLO C, MAGRO L, et al.Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy[J]. Expert Opin Drug Saf, 2014, 13(Supp1): 21-29.